NMDA receptor gluN2A/gluN2B subunit ratio as synaptic trait of levodopa-induced dyskinesias : from experimental models to patients by M. Mellone et al.
ORIGINAL RESEARCH
published: 06 July 2015
doi: 10.3389/fncel.2015.00245
NMDA receptor GluN2A/GluN2B
subunit ratio as synaptic trait of
levodopa-induced dyskinesias: from
experimental models to patients
Manuela Mellone 1‡, Jennifer Stanic 1‡, Ledia F. Hernandez 2, Elena Iglesias 2, Elisa Zianni 1,
Annalisa Longhi 1, Annick Prigent 3,4,5,6, Barbara Picconi 7, Paolo Calabresi 7,8, Etienne C.
Hirsch 3,4,5,6, Jose A. Obeso 2†, Monica Di Luca 1 and Fabrizio Gardoni 1*
1 Dipartimento di Scienze Farmacologiche e Biomolecolari (DiSFeB), Università degli Studi di Milano, Milano, Italy, 2 Movement
Disorders Group, Neurosciences Division, Center for Applied Medical Research (CIMA), Center for Networked Biomedical
Research on Neurodegenerative Diseases (CIBERNED), University of Navarra, Pamplona, Spain, 3 Inserm, U 1127, Paris,
France, 4 CNRS, UMR 7225, Paris, France, 5 Sorbonne Universités, UPMC Univ Paris 06, UMR S 1127, Paris, France,
6 Institut du Cerveau et de la Moelle Épinière, ICM, Paris, France, 7 Fondazione Santa Lucia, IRCCS, Rome, Italy, 8 Clinica
Neurologica, Dipartimento di Medicina, Università degli Studi di Perugia, Ospedale Santa Maria della Misericordia, Localitá,
Sant’Andrea delle Fratte, Perugia, Italy
Edited by:
Fabio Blandini,
National Institute of Neurology
C. Mondino Foundation, Italy
Reviewed by:
Stefano Taverna,
San Raffaele Hospital, Italy
Marie Therese Fuzzati-Armentero,
IRCCS Fondazione Istituto
Neurologico Nazionale C. Mondino,
Italy
*Correspondence:
Fabrizio Gardoni,
Dipartimento di Scienze
Farmacologiche e Biomolecolari
(DiSFeB), Università degli Studi
di Milano, via Balzaretti 9,
20133 Milano, Italy
fabrizio.gardoni@unimi.it
†Present address:
Jose A. Obeso,
Centro Integral de Neurociencias AC
(CINAC), Hospital HM-Puerta del Sur
Fundacion Hospital de Madrid and
CEU-San Pablo University, Madrid,
Spain
‡These authors have contributed
equally to this work.
Received: 06 May 2015
Accepted: 17 June 2015
Published: 06 July 2015
Citation:
Mellone M, Stanic J, Hernandez LF,
Iglesias E, Zianni E, Longhi A,
Prigent A, Picconi B, Calabresi P,
Hirsch EC, Obeso JA, Di Luca M and
Gardoni F (2015) NMDA receptor
GluN2A/GluN2B subunit ratio as
synaptic trait of levodopa-induced
dyskinesias: from experimental
models to patients.
Front. Cell. Neurosci. 9:245.
doi: 10.3389/fncel.2015.00245
Levodopa-induced dyskinesias (LIDs) are major complications in the pharmacological
management of Parkinson’s disease (PD). Abnormal glutamatergic transmission in
the striatum is considered a key factor in the development of LIDs. This work aims
at: (i) characterizing N-methyl-D-aspartate (NMDA) receptor GluN2A/GluN2B subunit
ratio as a common synaptic trait in rat and primate models of LIDs as well as in
dyskinetic PD patients; and (ii) validating the potential therapeutic effect of a cell-
permeable peptide (CPP) interfering with GluN2A synaptic localization on the dyskinetic
behavior of these experimental models of LIDs. Here we demonstrate an altered ratio
of synaptic GluN2A/GluN2B-containing NMDA receptors in the striatum of levodopa-
treated dyskinetic rats and monkeys as well as in post-mortem tissue from dyskinetic
PD patients. The modulation of synaptic NMDA receptor composition by a cell-
permeable peptide interfering with GluN2A subunit interaction with the scaffolding
protein postsynaptic density protein 95 (PSD-95) leads to a reduction in the dyskinetic
motor behavior in the two animal models of LIDs. Our results indicate that targeting
synaptic NMDA receptor subunit composition may represent an intriguing therapeutic
approach aimed at ameliorating levodopa motor side effects.
Keywords: NMDA receptor, Parkinson’s disease, levodopa-induced dyskinesias, 6-OHDA rat model, MPTP
monkey model, patients, cell-permeable peptides, striatum
Introduction
Glutamatergic transmission is greatly involved in the pathophysiology of Parkinson’s disease
(PD) and more specifically in levodopa (L-DOPA)-induced dyskinesias (LIDs; Calabresi
et al., 2010). After chronic treatment with L-DOPA, the glutamatergic signaling from the
cortex to the striatum undergoes adaptive changes which result in the aberrant functioning
of N-methyl-D-aspartate receptors (NMDARs) at the dendritic spine of striatal medium
spiny neurons (MSNs; Sgambato-Faure and Cenci, 2012; Mellone and Gardoni, 2013). NMDAR
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antagonists have been shown to exert a beneficial effect in
reducing the development of dyskinesias in experimental models
of LIDs (Hadj Tahar et al., 2004; Wessell et al., 2004). Most
importantly, they have been tested in clinical trials to reduce the
receptor activity in L-DOPA-treated dyskinetic patients (Nutt
et al., 2008). In particular, the NMDAR antagonist amantadine
exerts an anti-dyskinetic effect in PD patients (Luginger et al.,
2000; da Silva-Júnior et al., 2005; Sawada et al., 2010; Elahi et al.,
2012).
Besides NMDAR overactivation, a large number of studies
have indicated that the expression and the synaptic distribution
of specific NMDAR subtypes have a role in PD and LIDs (Picconi
et al., 2004; Hallett et al., 2005; Gardoni et al., 2006; Feng
et al., 2014; Zhang et al., 2014). In the 6-hydroxydopamine
(6-OHDA) rat model of PD, dopamine denervation influences
NMDAR subunit composition depending on the extent of
DA depletion (Gardoni et al., 2006; Paillé et al., 2010).
Chronic L-DOPA treatment also results in an abnormal
NMDAR composition at MSN dendritic spines. Specifically,
GluN2B subunit is aberrantly distributed to the extrasynaptic
membrane in the striatum of L-DOPA-treated dyskinetic rats,
while the synaptic levels of GluN2A are augmented (Gardoni
et al., 2006). Notably, alterations in the synaptic NMDAR
GluN2A/GluN2B subunit ratio in the striatum correlate with
the motor behavior abnormalities observed in rat models
of PD and LIDs (Gardoni et al., 2006, 2012; Paillé et al.,
2010). In particular, we previously demonstrated that 6-
OHDA lesioned rats chronically treated with L-DOPA but
not showing LIDs have a normal GluN2A/GluN2B ratio at
synapses (Gardoni et al., 2006). Prevention of the aberrant
NMDAR GluN2A/GluN2B subunit ratio at striatal excitatory
synapses by concomitant chronic administration of L-DOPA
and TAT2A, a cell-permeable peptide (CPP) interfering with
the interaction between GluN2A and the scaffolding protein
postsynaptic density protein 95 (PSD-95), is sufficient to
significantly reduce the onset of LIDs in parkinsonian rats
(Gardoni et al., 2012). Such CPP approach appears as a
promising putative anti-dyskinetic treatment in PD. However,
these encouraging results need validation in primate models
of LIDs as well as target confirmation in post-mortem tissue
from L-DOPA-treated dyskinetic PD patients. Furthermore,
future clinical evaluation of the efficacy of CPPs targeting
NMDARs will likely be focused on PD patients already
showing a dyskinetic behavior. Accordingly, in this work: (i) we
evaluated NMDAR subunit composition at striatal synapses of
parkinsonian and dyskinetic rats, monkeys and PD patients;
and (ii) we explored the potential therapeutic effect of TAT2A
administration to rats and monkeys with established and
consolidated dyskinesia.
Materials and Methods
Animals
Adult male Sprague Dawley rats (125–175 g; Charles River
Laboratories, Calco, Italy) were used in this study. Rats were
maintained on a 12 h light/dark cycle in a temperature-controlled
room (22◦C) with free access to food and water. All procedures
were performed in accordance with the current European Law
and were approved by the ItalianMinistry of Health (as indicated
in Dlgs N. 295/2012-A). 25 male non-human primates (Macaca
fascicularis) weighing 3–6 kg and at the age of 3–7 years
old (young adults) were sourced from R.C. Hartelust BV
(Tilburg, Netherlands). Animals were housed in an animal room
under standard conditions and treated in accordance with the
European and Spanish guidelines (86/609/EEC and 2003/65/EC
European Council Directives; and the Spanish Government). The
Bioethics Committee of the Universidad de Navarra approved
the experiments.
Cell-Permeable Peptides (CPPs)
Active (TAT2A; YGRKKRRQRRR-KMPSIESDV) and control
(TAT; YGRKKRRQRRR) CPPs were synthetized by Bachem
(Bubendorf, Switzerland) according to our designed sequences.
Lyophilized CPPs were solubilized in sterile deionized water to a
stock concentration of 1 mM and stored at−20◦C before use.
Antibodies
The following unconjugated primary antibodies were used:
mouse monoclonal (mAb) anti-GluN2B and anti-PSD-95
(1:2000, #75–097 clone 59/20 and #75028, Neuromab, Davis, CA,
USA); rabbit polyclonal (rAb) anti-GluN2A (1:1000) and mAb
anti-alpha-tubulin (1:10,000, #M264 and #T9026 respectively,
Sigma-Aldrich, St. Louis, MO, USA); rAb anti-MAP2 (1:500,
#AB5622, Merck-Millipore, Billerica, MA, USA); mAb anti-
HIV1 TAT antibody (1:200, #63957, Abcam, Cambridge, UK).
Goat AlexaFluor 488- and 555-conjugated anti-mouse and
anti-rabbit secondary antibodies (both 1:250, #A11029 and
#A21429, Life Technologies, Monza, Italy) were used for
immunofluorescence studies, while goat anti-mouse or anti-
rabbit horseradish peroxidase (HRP)-conjugated antibodies
were bought from Bio-Rad (both 1:10,000, #172–1011 and
#172–1019, Hercules, CA, USA) for western blot (WB)
analysis.
6-Hydroxydopamine (6-OHDA) Rat Model
Rats (n = 100) were unilaterally lesioned with 6-OHDA (Sigma-
Aldrich; 12 µg/4 µl, rate of injection 0.38 µl/min; stereotaxic
injection in the medial forebrain bundle, MFB, AP: −4.4, L:
+1.2; DV: −7.5) as previously reported (Picconi et al., 2008).
Fifteen days after the lesion, the rats were tested with 0.05 mg/kg
subcutaneous injection of apomorphine (Sigma-Aldrich), and
the contralateral turns were counted for 40 min. Only those
animals able to perform at least 200 contralateral turns
following apomorphine injection were used for the behavioral
and molecular experiments (fully lesioned rats, approximately
70% of the lesioned rats; Paillé et al., 2010). The severity of
the lesion was also quantified evaluating the levels of striatal
tyrosine hydroxylase (TH; #AB152, Merck-Millipore) by WB
analysis.
L-DOPA-Induced Dyskinesias and TAT2A
Treatment in 6-OHDA-Lesioned Rats
Two months after the stereotaxic injection of 6-OHDA, eight
fully lesioned rats were sacrificed and the ispilateral (6-OHDA I)
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and controlateral (6-OHDA C) striata were collected for
molecular studies. The remaining fully lesioned rats were treated
with 6 mg/kg L-DOPA (Sigma-Aldrich) combined with 6 mg/kg
benserazide (Sigma-Aldrich), 1 s.c. injection/day for 14 days. L-
DOPA-induced abnormal involuntary movements (AIMs) were
evaluated on days 4, 7, 10 and 14 of L-DOPA administration
using a highly validated rat AIMs scale (Cenci et al., 1998;
Lundblad et al., 2002; Picconi et al., 2003; Gardoni et al.,
2006). Briefly, rats were observed individually for 1 min every
20 min from 20 to 140 min after the L-DOPA injection. At
each observation time point the AIMs were classified into three
subtypes: (i) axial (dystonic or choreiform torsion of the upper
part of the body toward the side contralateral to the lesion);
(ii) limb (jerky and/or dystonic movements of the forelimb
contralateral to the lesion); and (iii) orolingual (empty jaw
movements and tongue protrusion). Each of these subtypes was
scored on a severity scale from 0 to 4, where 0 = absent, 1 =
present during less than half of the observation time (<30 s),
2 = present for more than half of the observation time (>30 s),
3 = present all the time (=1 min) but suppressible by external
stimuli, and 4 = present all the time and not suppressible by
external stimuli. The total AIM score for each test session was
obtained by summing the scores of all observation time points.
The rats that reached an AIMs score per session that was equal
to or higher than 25 were included in the dyskinetic group
(approximately 60% of the rats which were treated with L-
DOPA). For the molecular studies, eight rats per group were
sacrificed 1 h after the last daily L-DOPA injection (Gardoni
et al., 2006).
Following chronic administration of L-DOPA, dyskinetic rats
underwent a single stereotaxic injection of 1 nmol (n = 4), 5 nmol
(n = 5), 10 nmol (n = 6) TAT2A or 5 nmol TAT as control
(n = 6) in the striatum ipsilateral to the 6-OHDA lesion site
(rate of injection 0.5 µl/min; AP = +0.2, L = +3.5, DV = −5.7)
at day 15–19 of L-DOPA treatment. Six untreated dyskinetic
rats were used as further control. L-DOPA administration was
continued for 1 day after CPP injection (30 h). To evaluate
the effects of these CPPs on LIDs, behavioral assessments (AIM
score) on TAT/TAT2A-injected rats were carried out in double-
blinded conditions the day before the surgery (18 h before CPPs
stereotaxic injection), on the day of the surgery and the following
day (6 and 30 h after CPPs stereotaxic injection).
1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine
(MPTP) Monkey Model
Monkeys were treated with 0.5 mg/kg MPTP (i.v., femoral vein)
every 2 weeks for a variable period of 2–4 months to reach
different degrees of nigro-striatal lesion and parkinsonism (Blesa
et al., 2010, 2012) determined by the total number of doses and
variable individual susceptibility to MPTP when using a slow
intoxication protocol. In this study, eight animals were used as
control and 17 monkeys were treated with MPTP. Motor deficit
was assessed weekly by Kurlan motor scale which ranges from 0
to 29 (Kurlan et al., 1991). 17 monkeys developed parkinsonian
features with the first 1–2 MPTP injections. Five monkeys did
not receive any furtherMPTP injection and exhibited progressive
improvement until motor behavior had normalized (score 0–1)
and are labeled as recovered monkey (Mounayar et al., 2007).
The remaining 12 monkeys continued to receive MPTP as
explained above to achieve stable moderate parkinsonism (n =
5; Kurlan’s score 8–15) and severe parkinsonism (n = 7; Kurlan’s
score > 16). Each animal remained stable for at least 1 month in
the corresponding motor state before initiating treatment (Blesa
et al., 2012).
L-DOPA-Induced Dyskinesias and TAT2A
Treatment in Monkeys
Parkinsonian monkeys with severe symptoms were chronically
treated with L-DOPA to induce dyskinesia. L-DOPA
(50–55 mg/kg, i.p.) was injected daily until a stable dyskinetic
behavior was achieved (6 months). The severity of dyskinesia
was scored daily blindly using a scale which is used in the clinical
practice. This rating system assesses both severity (0–3) and
duration (0–3) of the dyskinetic movements in different body
parts including the four limbs, the trunk and the face (Luquin
et al., 1992). Animals were sacrificed after 3 months of chronic
treatment with L-DOPA for brain tissue analysis. The brain
was removed and fresh frozen. Tissue from head of caudate,
anterior and posterior putamen was collected for the subcellular
fractionation studies.
Three MPTP parkinsonian monkeys previously made
dyskinetic with L-DOPA as explained above were used to test the
potential antidyskinetic effect of TAT2A. Three TAT2A doses of
3, 4.5 and 6 nmol/g were given intraperitoneally 30 min before
L-DOPA administration in different study days.
One monkey received the 3 nmol/g dose twice with no effect
whatsoever. Thus, TAT2A dose was increased to 4.5 nmol/g and
6 nmol/g in the threemonkeys. Dyskinesia score wasmeasured as
described above. A 1-week period in-between peptide injections
was taken as washout. L-DOPA treatment was continued on a
daily basis.
Post-Mortem Tissue from Human Subjects
Post-mortem brain material (putamen) from PD patients (n =
16; see Table 1) and age-matched control subjects (n = 16)
were used in this study. Control brains were obtained from
individuals without neurologic or psychiatric disorders. Patients
with PD displayed the characteristics of the disease including
akinesia, rigidity and/or resting tremor. All patients with
PD were treated with L-DOPA and/or dopaminergic agonists
and/or anti-cholinergic agents and displayed or had displayed
dyskinesia (see Table 1). The clinical diagnosis was confirmed
by neuropathological examination. Mean post-mortem delay
and age at death did not differ between control subjects and
patients with PD. At autopsy the brain was removed and hemi-
sected: one hemisphere was formalin fixed for neuropathological
confirmation of the diagnosis and the other half was dissected
and flash frozen. All brains showed neuronal loss in the
substantia nigra and Lewy bodies detected by hematoxylin-eosin
staining. The putamen was dissected out from the striatum,
frozen and reduced to power on dry ice. Frozen tissue was
pooled from the whole structure from each patient. Then 10 to
15 mg of putamen were prepared for each subject and used for
biochemical measurements.
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TABLE 1 | Table summarizing the clinical data of patients from which brain samples were obtained.
PARK N◦ Age (years) Post-mortem delay (hours) Sex Disease duration (years) Treatment
1 69 24 M 9 Madopar (benserazide
hydrochloride/levodopa)
2 66 <26 M 13 Madopar (benserazide
hydrochloride/levodopa)
3 59 <24 M 25 Madopar (benserazide
hydrochloride/levodopa)
4 82 15 M 6 Madopar (benserazide
hydrochloride/levodopa),
Parlodel (bromocriptine)
5 57 15 F 15 Madopar (benserazide
hydrochloride/levodopa)
6 67 11 M 14 Madopar (benserazide
hydrochloride/levodopa),
Artane (Trihexyphenidyl)
7 75 8 M 7 Madopar (benserazide
hydrochloride/levodopa)
8 77 3 M 15 Madopar (benserazide
hydrochloride/levodopa)
9 83 11 F 2 Madopar (benserazide
hydrochloride/levodopa),
Artane (Trihexyphenidyl)
10 84 10 M 20 Madopar (benserazide
hydrochloride/levodopa),
Artane (Trihexyphenidyl)
11 69 12 M 16 Madopar (benserazide
hydrochloride/levodopa),
Artane (Trihexyphenidyl),
12 68 <24 M 2 Madopar (benserazide
hydrochloride/levodopa)
13 79 15 F Unknown Unknown
14 76 12 M 35 Madopar (benserazide
hydrochloride/levodopa),
Artane (Trihexyphenidyl)
15 77 <24 M 10 Madopar (benserazide
hydrochloride/levodopa)
16 84 37 F 4 Madopar (benserazide
hydrochloride/levodopa)
Subcellular Fractionation
Subcellular fractionation was performed as previously described
(Gardoni et al., 2006) with only few modifications. Briefly,
striata were homogenized with a hand-held Teflon-glass
homogenizer in ice-cold buffer (pH 7.4) containing 0.32 M
sucrose, 1 mM Hepes, 1 mM MgCl2, 1 mM NaHCO3 and
0.1 phenylmethanesulfonylfluoride (PMSF) in the presence of
Complete Protease Inhbitor Cocktail Tablets (Roche Diagnostics,
Basel, Switzerland) and phosSTOP Phosphatase Inhibitor
Cocktail Tablets (Roche Diagnostics, Basel, Switzerland). The
contralateral striatum of fully 6-OHDA lesioned rats was used
as control. An aliquot of the homogenate was stored at −20◦C,
while the rest of the sample was centrifuged at 800 g for 5 min to
remove nuclear contamination and white matter. The resulting
supernatant was spun at 13,000 g for 15 min at 4◦C to obtain
a crude membrane fraction (P2 fraction) as a pellet which was
resuspended with a glass-glass homogenizer in 1 mM Hepes
supplemented with Complete Cocktail. An aliquot of the P2
fraction was stored at−20◦C for co-immunoprecipitation assays,
whereas the rest of the sample was centrifuged at 100,000 g for
1 h at 4◦C. The new pellet was resuspended in 75 mM KCl and
1% Triton X-100 and spun at 100,000 g for 1 h at 4◦C. The final
pellet was homogenized in a glass-glass potter in 20 mM Hepes
supplemented with Complete tablets and then stored at −80◦C.
This fraction was referred to as Triton X-100-insoluble fraction
(TIF). We isolated the TIF instead of the classical PSD because
the amount of the startingmaterial was often limited. The protein
composition of the TIF was carefully tested for the absence of
presynaptic markers (Gardoni et al., 2006). Similar TIF yields
were obtained from striata of all experimental groups.
Co-Immunoprecipitation Assay
P2 fraction (50 µg) from the striatum of parkinsonian,
dyskinetic and control rats were incubated in radio
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-immunoprecipitation assay (RIA) buffer [200 mM NaCl,
10 mM ethylenediaminetetraacetic acid (EDTA), 10 mM
Na2HPO4, 0.5% Nonidet P-40] supplemented with 0.1% sodium
dodecyl sulfate (SDS) and anti-PSD-95, anti-GluN2A or anti-
GluN2B antibodies. Samples were incubated overnight at 4◦C
on a wheel. Protein A/G-agarose beads (Santa Cruz, Dallas,
TX, USA) were added and incubation was continued for 2 h at
room temperature (RT) on the wheel. Beads were collected and
washed four times in RIA buffer containing 0.1% SDS. Laemmli
sample buffer was then added to the beads and the mixture was
boiled for 10 min. Beads were pelleted by centrifugation and the
supernatant was loaded onto an acrylamide/bisacrylamide gel
for SDS-PAGE.
Western Blot (WB)
Protein samples were separated onto 7–9%
acrylamide/bisacrylamide gel, transferred to a nitrocellulose
membrane and probed with the appropriate primary and HRP-
conjugated secondary antibodies. Labeling was visualized by
Chemidoc and ImageLab software (Biorad). Western blot (WB)
quantification was performed using ImageLab software.
Free-Floating Immunohistochemistry
5(6)-FAM-conjugated TAT2A peptide was administrated to
adult male non-human primates (i.p.) 30 min before sacrifice.
Control monkeys were injected with the vehicle. The brain was
dissected and post-fixed in 4% paraformaldehyde (PFA) in 0.1
M tris buffered saline (TBS) followed by sequential sinking in
20% and 30% sucrose in TBS. The tissue was then sectioned
using a microtome and 40 µm-thick slices were stored in
a cryoprotective solution at −20◦C until use. Antigens were
retrieved with 10 mM sodium citrate pH 6. Tissue sections were
permeabilized in TBS containing 0.4% Triton X-100 (0.4% T-
TBS) for 30 min at 4◦C. After blocking in 5% Normal Goat
Serum (NGS, #G9023, Sigma-Aldrich) in 0.1% T-TBS for 2 h
at RT, slices were incubated with anti-HIV1 TAT and anti-
microtubule associated protein 2 (MAP2) antibodies in 3%
NGS-0.1% T-TBS overnight at 4◦C. Tissue sections were then
incubated with the appropriate AlexaFluor secondary antibodies
in 3% NGS-TBS for 2 h at RT. Nuclei were stained with
the fluorescent dye 4′,6-diamidino-2-phenylindole (DAPI, Life
Technologies, Carlsbad, CA, USA). Slices were finally mounted
with Fluoromount mounting medium (Sigma-Aldrich) onto
glass slides. Labeling was visualized with LSM510 Meta system
confocal microscope (Zeiss, Oberkochen, Germany) and Aim 4.2
software (Zeiss).
Statistics
Data were analyzed using GraphPad Prism version 6 (GraphPad
Software, La Jolla, CA, USA). Data followed a normal
distribution and the significance of the differences was analyzed
by unpaired two-tailed Student’s t-test/one-way or two-way
ANOVA followed by Bonferroni or Tukey post hoc tests as
appropriate. Details of the statistical analysis applied in this work
and the p values are given in the ‘‘Results’’ Section and/or in the
Figure legends. Data are presented as mean± SEM.
Results
Chronic L-DOPA Treatment Increases
GluN2A/GluN2B Subunit Ratio at Striatal
Synapses in Animals Showing a Dyskinetic
Motor Behavior
Levels of NMDAR regulatory subunits were analyzed by WB
in homogenate and postsynaptic fraction (Triton-insoluble
fraction, TIF) from the ipsilateral (6-OHDA I) and contralateral
(6-OHDA C) striata of fully 6-OHDA-lesioned rats and the
ipsilateral striatum of L-DOPA-treated (6 mg/kg per day)
dyskinetic rats (DYS; Figure 1A). Similar TIF protein yields were
obtained from all groups, and the same amount of proteins was
used for SDS-PAGE. As previously reported (Gardoni et al.,
2006), no differences in the expression level of any of the
tested NMDAR subunits were observed in the homogenate
from the three experimental groups (data not shown). On
FIGURE 1 | Chronic L-DOPA treatment increases GluN2A/GluN2B
subunit localization at synaptic sites in 6-OHDA rats displaying
dyskinetic behavior. (A) WB for GluN2A, GluN2B and tubulin of TIF
samples from the ipsilateral (6-OHDA I) and the contralateral (6-OHDA C)
striata of 6-OHDA-lesioned rats and the ipsilateral striatum of
L-DOPA-treated (6 mg/kg/die) dyskinetic animals (DYS). GluN2A/GluN2B
ratio is increased in dyskinetic rats (**p < 0.01). (B) Co-immunoprecipitation
of GluN2A and PSD-95 in P2 fractions from the ipsilateral (6-OHDA I) and the
contralateral (6-OHDA C) striata of 6-OHDA-lesioned rats and the ipsilateral
striatum of L-DOPA-treated (6 mg/kg/die) dyskinetic rats (DYS). The
interaction between GluN2A and PSD-95 is augmented in the crude
membrane fraction of dyskinetic animals (**p < 0.01).
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the contrary, chronic L-DOPA administration determined a
significant increase in the synaptic ratio of GluN2A/GluN2B
subunits compared to controls and 6-OHDA-lesioned rats
(Figure 1A; ∗∗∗p < 0.001 one-way ANOVA; Bonferroni post
hoc test, DYS vs. 6-OHDA I: ∗∗p < 0.01, DYS vs. 6-OHDA
C: ∗∗p < 0.01). These results are in agreement with what was
previously described in dyskinetic rats exposed to a higher
(20 mg/kg per day) dose of L-DOPA (Gardoni et al., 2006). We
then tested whether the observed alterations in GluN2A/GluN2B
synaptic abundance correlated with changes in the receptor
interaction with members of the membrane-associated guanylate
kinases (MAGUK) family such as the scaffolding protein PSD-
95. Dyskinetic rats showed an increased binding between
GluN2A and PSD-95, thus favoring the anchoring of such
NMDAR subtype at the synaptic compartment (Figure 1B;
∗∗p < 0.01 one-way ANOVA; Bonferroni post hoc test, DYS
vs. 6-OHDA I: ∗∗p < 0.01, DYS vs. 6-OHDA C: ∗∗p <
0.01).
The 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-
treated macaque is still considered the gold standard animal
model for PD as it shares several features of the human
disease (Bezard and Przedborski, 2011; Blesa et al., 2012;
Porras et al., 2012). Accordingly, to strengthen the relevance
of the data from the rodent experimental model, we decided
to expand our analysis on NMDAR subunit composition to
MPTP-treatedmonkeys (Figure 2) and post-mortem brain tissue
from dyskinetic PD patients as a key step for target validation
(Figure 3). Protein levels of NMDAR subunits were evaluated by
WB in postsynaptic fractions from the striatum of control and
MPTP-treated monkeys with mild or severe motor alterations.
GluN2A/GluN2B ratio was significantly increased at synapses
from both MPTP-mild (Figure 2A) and severe (Figure 2B)
parkinsonian monkeys (MPTP-mild or MPTP-severe vs. control
animals: ∗p < 0.05, two-tailed unpaired Student’s t-test). In
contrast, NMDAR subunit levels were normal in moderately
lesionedMPTPmonkeys (Figure 2A; MPTP rec group vs. control
animals: p > 0.05, two-tailed unpaired Student’s t-test).
In addition, abnormal GluN2A/GluN2B ratio at striatal
synapses was also detected in L-DOPA-treated MPTP-monkeys
displaying a dyskinetic motor behavior (Figure 2C; DYS vs.
controls: ∗p < 0.05 two-tail unpaired Student’s t-test). No
changes in NMDAR subunit expression in the homogenate
from MPTP-mild, MPTP-severe or L-DOPA-treated dyskinetic
animals were found when compared to control monkeys (data
not shown). Finally, when we checked for the interaction with
the scaffolding protein PSD-95 in the dyskinetic macaques, we
observed an increased binding of GluN2A to PSD-95 (Figure 2D;
GluN2A/PSD-95 DYS vs. controls: ∗p < 0.05), which was not
replicated with GluN2B (data not shown). Altogether, these
results indicate that NMDAR composition is reorganized not
only in the rat model but also in this highly validated primate
model of PD and LIDs.
FIGURE 2 | DA denervation and chronic L-DOPA treatment increases
GluN2A/GluN2B subunit ratio at synaptic sites in the MPTP-monkey
model. (A) WB for GluN2A, GluN2B and tubulin of TIF samples from the
striatum of control (C), MPTP-treated monkeys with mild motor alterations
(MPTP mild; *p < 0.05) and mild parkinsonian monkeys which had fully
recovered by interruption of MPTP treatment (MPTP rec). (B) WB for GluN2A,
GluN2B and Tubulin of TIF samples from the striatum of control (C) and
MPTP-treated monkeys with severe motor alterations (MPTP severe;
*p < 0.05). (C) WB for GluN2A, GluN2B and Tubulin of TIF samples from the
striatum of control (C) and dyskinetic MPTP-treated monkeys (DYS;
*p < 0.05). (D) GluN2A subunit was immunoprecipitated and its binding to
PSD-95 was analyzed by WB in the striatum of control (C) and dyskinetic
MPTP-treated monkeys (DYS). GluN2A and PSD-95 binding was significantly
increased (*p < 0.05).
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FIGURE 3 | Chronic L-DOPA treatment increases GluN2A/GluN2B
subunit ratio at synaptic sites in dyskinetic Parkinson’s disease (PD)
patients. (A) WB for GluN2A, GluN2B and Tubulin of homogenates and TIF
samples from the striatum of control (C) and dyskinetic PD patients (PD). (B,C)
Quantification of GluN2A and GluN2B subunits in homogenates (B) and TIF
fractions (C) from dyskinetic PD patients and control subjects. The analysis
showed a statistically significant increase in GluN2A synaptic localization and
the subsequent alteration of GluN2A/GluN2B subunit ratio at synapses of
dyskinetic PD patients (*p < 0.05; ***p < 0.001). No changes were found in
homogenates.
Furthermore, post-mortem material from the putamen of
dyskinetic PD patients (see Table 1) and age-matched control
subjects (C) was analyzed by WB (Figure 3A). No changes in
NMDAR GluN2A and GluN2B subunit levels were detected
in the homogenates (Figures 3A,B; PD vs. C: p > 0.05, two-
tailed unpaired Student’s t-test). However, PD patients were
characterized by a significant increase in the synaptic localization
of GluN2A but not GluN2B (Figures 3A,C, TIF fraction;
GluN2A PD vs. C: ∗p < 0.05, GluN2B PD vs. C: p > 0.05, two-
tailed unpaired Student’s t-test). Overall, these changes led to a
significant increase in GluN2A/GluN2B subunit ratio at synaptic
sites in PD patients compared to control subjects (Figures 3A,C,
TIF fraction; GluN2A/GluN2B PD vs. C: ∗∗∗p< 0.001, two-tailed
unpaired Student’s t-test).
Altogether, our data highlight molecular modifications of
NMDAR composition in two different models of experimental
parkinsonism and LIDs, and in the human pathology. Moreover,
changes in the interaction between the receptor subunits and
members of the MAGUK family are present in 6-OHDA
dyskinetic rats and MPTP dyskinetic monkeys.
TAT2A Peptide Ameliorates the Severity of
Established Dyskinesias through the
Dissociation of GluN2A Subunit from PSD-95
To rebalance synaptic NMDAR composition, we focused on
the mechanisms regulating GluN2A localization at the synaptic
compartment. In particular, we took advantage of the CPP
approach to disrupt GluN2A binding to scaffolding proteins of
the MAGUK family. We have previously shown that a chronic
concomitant treatment with L-DOPA and a CPP targeting
GluN2A/PSD-95 interaction (TAT2A) was able to reduce
the number of 6-OHDA-lesioned rats developing dyskinetic
movements (Gardoni et al., 2012). However, from a clinical
point of view, to determine the anti-dyskinetic potential of a
compound, it is necessary to evaluate its ability to reduce the
severity of already established LIDs. Therefore, we evaluated
whether administration of TAT2A to dyskinetic rats after chronic
treatment with L-DOPA could have beneficial effects on their
behavior. TAT2A or TAT control peptides were stereotaxically
injected in the ipsilateral striatum of 6-OHDA-lesioned rats
chronically treated with L-DOPA and displaying dyskinetic
motor behavior (AIMs score ≥ 25; see ‘‘Materials and Methods’’
Section). CPPs were injected 6 h before the daily L-DOPA
administration and the evaluation of AIMs was carried out from
20 to 140 min after L-DOPA (Figures 4A,B). 5 and 10 nmol
TAT2A were able to induce a significant reduction of the AIMs
score (Figure 4A; two-way ANOVA F(8,44) = 3.076, p < 0.01;
Tukey post hoc test, TAT2A 5 nmol: −18 vs. 6 h, ∗p < 0.05;
TAT2A 10 nmol: −18 vs. 30 h, ∗∗∗p < 0.001, 6 vs. 30 h, ∗p
< 0.05. 30 h: TAT vs. TAT2A 5 nmol, ◦p < 0.05, TAT vs.
TAT2A 10 nmol, ◦◦◦p < 0.001, TAT2A 10 nmol vs. DYS, ##p <
0.01). Moreover, the time course of AIMs development showed
that both TAT2A peptide dosages significantly decreased AIMs
induction, measured during the single last observation session
(Figure 4B; 30 h: One-way ANOVA, Tukey post hoc test: 20 min:
p > 0.05; 40 min: p > 0.05; 60 min: #p < 0.05, TAT vs. TAT2A
10 nmol, ◦p< 0.05; 80 min: ##p< 0.01, TAT vs. TAT2A 10 nmol,
◦p < 0.05, TAT vs. TAT2A 5 nmol ∗p < 0.05; 100 min: #p <
0.05, TAT vs. TAT2A 10 nmol, ◦p < 0.05; 120 min: p > 0.05;
140 min: #p < 0.05). No effect was observed following injection
of 1 nmol TAT2A in agreement with previous data (Gardoni
et al., 2012). No difference was observed in rats treated with
TAT control peptide compared to untreated dyskinetic rats, thus
demonstrating the absence of any effect induced by the surgery
procedure or by the TAT moiety (Figure 4A).
To assess the potential therapeutic effect on the non-human
primate model, we tested TAT2A peptide on a limited number
of dyskinetic monkeys (n = 3). Before the evaluation of the effect
of TAT2A on the motor behavior, we first verified the ability of
this CPP to cross the blood brain barrier, reach the brain and
enter neurons. One monkey was injected (i.p.) with a labeled
TAT2A peptide while another one received the vehicle 30 min
before their sacrifice. The prefrontal cortex was fixed, sliced
and immunostained with an antibody against the TAT sequence
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FIGURE 4 | TAT2A peptide ameliorates the severity of established
dyskinesia. (A) Decrease in the dyskinesia score of 6-OHDA rats treated
with L-DOPA after 6 h and 30 h from the intrastriatal injection of TAT2A
(*,◦p < 0.05, ##p < 0.01, ***,◦◦◦p < 0.001). (B) Reduction of AIMs
induction in TAT2A 5 or 10 nmol injected animals in the session test
30 h after CPP injection (*,◦ ,#p < 0.05, ##p < 0.01).
(C) Immunohistochemistry for TAT sequence (green) and MAP2 (as
neuronal marker, red) from the brain of monkeys treated with a
5(6)-FAM-conjugated TAT2A peptide or the vehicle. Nuclei were labeled
with DAPI (blue). Scale bar: 40 µm; Insert scale bar: 10 µm.
(D) Reduction of the dyskinesia score in MPTP-monkeys after i.p. TAT2A
treatment 30 min before L-DOPA injection. The graph shows dyskinesia
scores (Y-axis) over the time course of levodopa (X-axis) at the three
doses of TAT2A (3 nmol/g; 4.5 nmol/g; 6 nmol/g) in the 3 MPTP
monkeys expressed as percentage of the dyskinesia score before TAT2A
treatment.
(green) and MAP2 (as neuronal marker, red; Figure 4C). While
no positive staining for TAT was detectable in the control
macaque (vehicle-injected), immunolabeling demonstrated that
TAT2A is able to reach the brain of non-human primates
and the peptide was clearly found in neuronal cells located
in the cortex (Figure 4C, insert). Monkeys that received L-
DOPA (50–55 mg/kg i.p.) for 6 months and exhibited a
persistent dyskinetic behavior were treated systemically with
TAT2A peptide at the doses of 3, 4.5 and 6 nmol/g 30 min
before the daily L-DOPA administration. Comparably to the
TAT2A treatment in rats, the higher dose used in this study
(6 nmol/g) was able to reduce the dyskinetic behavior with
the highest effect 60 min after L-DOPA injection. At this dose
we observed an average reduction in the dyskinesia score of
47.15% (n = 2, 2 days, Figure 4D). A 25% reduction was found
at 60 min with the 4.5 nmol/g dose (n = 3, 2 days), while
12.5% reduction was evident with 3 nmol/g TAT2A (n = 1,
2 days; Figure 4D). The anti-parkinsonian effect of L-DOPA
was maintained in the co-treatment with TAT2A (data not
shown).
Discussion
Altered subunit composition of striatal NMDARs have been
found to be involved in the pathophysiology of LIDs (Gardoni
et al., 2006, 2012; Calabresi et al., 2010; Mellone and Gardoni,
2013). However, a proof of concept of this hypothesis in well-
established rodent and primate models of LIDs as well as a
validation in human post-mortem tissue was not complete.
Our results demonstrate that a single intrastriatal injection of
a peptide (TAT2A) capable of reducing synaptic accumulation
of GluN2A-containing NMDARs leads to a dose-dependent
decrease of AIMs in L-DOPA-treated dyskinetic rats. Notably,
systemic administration of TAT2A peptide to MPTP-treated
monkey with established LIDs determined a dose-dependent
reduction of dyskinetic behavior comparable to what was
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observed in the rat 6-OHDA model. These results indicate
a cross-species validation of the efficacy of this therapeutic
approach.
So far NMDAR subunit expression in L-DOPA-treated
MPTP-lesioned non-human primates (Calon et al., 2002; Hallett
et al., 2005; Morin et al., 2013) and PD patients (Holemans
et al., 1991; Weihmuller et al., 1992; Calon et al., 2003)
has not been extensively investigated, and the few studies
available have been mainly carried out using a receptor
binding approach with radiolabeled ligands. Among these
reports, only a previous study from Hallett et al. (2005)
analyzed NMDARs subcellular distribution and they found that
dopamine depletion and subsequent replacement with L-DOPA
in MPTP-lesioned macaques induces significant alterations in
the abundance of striatal NMDAR subunits. In particular,
following chronic treatment with L-DOPA, they observed a
striking increase in the abundance of GluN2A subunit in
the synaptic membrane fraction (Hallett et al., 2005). The
significant increase in GluN2A/GluN2B subunit ratio that we
found in both parkinsonian and L-DOPA-treated dyskinetic
monkeys is consistent with these previous observations (Hallett
et al., 2005). Moreover, we observed a similar increase of
synaptic GluN2A/GluN2B ratio in dyskinetic PD patients which
highlights the relevance of therapeutically targeting GluN2A
clustering at synapses. Conversely, it is challenging to compare
our results with studies employing a ligand binding approach to
detect levels of NMDAR subunits. Previous studies on MPTP-
treated non-human primates (Calon et al., 2002; Morin et al.,
2013) did not observe significant changes in the binding of
ligands to the GluN2A subunit. Considering that these studies
were not performed in a fractionated tissue samples, it is
reasonable to compare themwith our western blotting performed
in a total cell homogenate where we did not find any alteration
of GluN2A or GluN2B subunits in parkinsonian as well as
L-DOPA-treated dyskinetic macaques. Similarly, no alterations
in GluN2A/GluN2B ratio from total striatal homogenates were
detected in monkeys, and notably in patients’ post-mortem
tissue. These results further support the idea that an abnormal
synaptic localization of specific subtypes of NMDARs rather than
their altered expression level represents the main event taking
place inMSNs excitatory synapses after L-DOPA administration.
Altogether, the above considerations support the applicability
of CPP interfering with GluN2A subunit clustering at the
excitatory synapse as therapeutic agent instead of the classical
receptor antagonist approach, which inhibits the activity of
surface NMDARs at both synaptic and extrasynaptic sites.
Accordingly, the previous failure to prevent the development of
LIDs in MPTP-treated primates using the GluN2A antagonist
MDL100,453 (Blanchet et al., 1999) can be explained both by
the low degree of selectivity for GluN2A over GluN2B of the
antagonist as well as by the lack of specificity towards synaptic
NMDARs.
We previously reported that the concomitant chronic
administration of L-DOPA and TAT2A was able to prevent the
onset of LIDs in the rat model (Gardoni et al., 2012). Here
we extend these earlier results, showing the efficacy of TAT2A
treatment in reducing LIDs also in animals with established
and consolidated dyskinesia. Notably, the absence of any effect
observed with single intrastriatal injection of 1 nmol TAT2A
is in agreement with the previous observation of a lack of
anti-dyskinetic activity following repeated injection of 0.5 nmol
TAT2A (Gardoni et al., 2012) and indicates an intrastriatal
injection of 5–10 nmol as the most appropriate dosage.
Interestingly, a previous study from our group also showed that
TAT2A rescued PDmotor symptoms and restored altered striatal
plasticity in 6-OHDA rats with a partial nigrostriatal lesion
(Paillé et al., 2010).
In the last decade, the clinical administration of CPPs
has been debated because of pharmacokinetic and economic
reasons. However, promising results from recent studies
have been supporting their use in preclinical and clinical
stages, clearly highlighting their therapeutic relevance (Bach
et al., 2011; Hill et al., 2012; Mellone and Gardoni, 2013).
An analogous peptide (Tat-GluN2B9c) targeting GluN2B-
containingNMDARs interactionwith PSD-95, which differs only
by two amino acids with the TAT2A peptide used in our study,
was recently tested in a phase 2 randomized double-blinded
placebo-controlled clinical trial for stroke (Hill et al., 2012).
Hill and co-authors demonstrated that Tat-GluN2B9c can be
safely administered to patients, strengthening the importance of
interference peptides in central nervous system disorders paving
the way for their future therapeutic application (Hill et al.,
2012). In addition, the production of small and potent plasma-
stable peptidomimetic compounds deriving from CPPs (Bach
et al., 2011) represents the possibility for a further improvement
and a more favorable clinical applicability of this therapeutic
intervention.
Our results demonstrate that altered GluN2A/GluN2B ratio
at striatal synapses represents a synaptic trait of LIDs in different
experimental models as well as in PD patients and indicate that
reduction of GluN2A synaptic abundance can represent a novel
strategy to counteract LIDs.
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